BELLEVUE, Wash., Oct. 7, 2009 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV), a biotechnology company specializing in the development of immunotherapeutic vaccines for cancer and infectious diseases, has received a Buy recommendation from Konrad Kuhn, editor and head analyst of the KonLin Newsletter.
The KonLin (www.konlin.com) is a known authority on equities under $10 with emphasis on emerging growth companies and special situations. For over 27 years it has constantly been a leading financial publication in that sector.
About TapImmune Inc.
TapImmune Inc. is a biotechnology company specializing in the development of innovative cell based immunotherapeutics and vaccines in the areas of oncology and infectious disease. The Company's AdhTAP vaccine is designed to restore and augment antigen presentation and subsequent recognition that result in the killing of cancer cells by the immune system. Additionally, management is currently preparing for clinical manufacturing and toxicology studies of AdhTAP. Short-term plans also include the development of a TAP based prophylactic vaccine that is designed to increase the efficacy of targeted prophylactic vaccines by up to 1000 times.
As a vaccine, the TAP technology could significantly improve the efficacy of many current prophylactic vaccines and enhance the creation of new ones in the fight against many pandemic infectious diseases. As a stand-alone cancer therapy or in combination with other drugs, AdhTAP could prove to be a key component of a more successful assault on cancer.
Website: www.TapImmune.com
The TapImmune Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3877
Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors, which could cause actual results to differ materially from those, stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K and other SEC filings, which are available through EDGAR at www.sec.gov. These are among the primary risks we foresee at the present time. The Company assumes no obligation to update the forward-looking statements.